SDG 3. GOOD HEALTH & WELL-BEING InterVenn Biosciences

InterVenn Biosciences Announces Clinical Validation of World’s First Glycoproteomic Diagnostic Test

June 10, 2021, by Business Wire Technology News

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #AI–InterVenn Biosciences announces it has completed clinical and analytical validation of GLORI, a liquid-biopsy diagnostic test for female pelvic tumors

Read more on Business Wire Technology News


SDG 3. GOOD HEALTH & WELL-BEING InterVenn Biosciences

InterVenn Biosciences Announces that Nobel Laureate James P. Allison, PhD, has Joined the Company’s Board of Advisors

April 15, 2021, by Business Wire Technology News

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #AI–Nobel Prize recipient James P. Allison joins InterVenn’s Board of Advisors as the company works to find new solutions for ...

Read more on Business Wire Technology News


SDG 3. GOOD HEALTH & WELL-BEING InterVenn Biosciences

InterVenn Biosciences Announces that Nobel Laureate James P. Allison, PhD, has Joined the Company’s Board of Advisors

April 15, 2021, by Business Wire Technology News

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #AI–Nobel Prize recipient James P. Allison joins InterVenn’s Board of Advisors as the company works to find new solutions for ...

Read more on Business Wire Technology News


SDG 3. GOOD HEALTH & WELL-BEING InterVenn Biosciences

InterVenn’s Glycoproteomic-based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint Inhibitors

April 13, 2021, by Business Wire Technology News

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #AI–InterVenn Biosciences, the leader in glycoproteomics, announced today that it has developed a glycoproteomics-based signature that accurately predicts which malignant ...

Read more on Business Wire Technology News


SDG 3. GOOD HEALTH & WELL-BEING InterVenn Biosciences

InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics Solutions

March 11, 2021, by Rédaction

Wednesday, January 13th 2021 at 1:02pm UTC Breakthrough Data on Predicting Immuno-Oncology Treatment Response, Additional Partnerships, and Pending Launch of Ovarian Cancer Test Expand Opportunities ...

Read more on EEI-BIOTECHFINANCES


HEALTH & WELL-BEING CANCER InterVenn Biosciences

InterVenn Biosciences raises $34 million to accelerate cancer test development with AI

November 17, 2020, by Kyle Wiggers

InterVenn Biosciences, a company developing an AI-imbued platform for diagnostic cancer test design, raised $34 million.Read More

Read more on VentureBeat